Multiplicity of effectors of the cardioprotective agent, diazoxide
- PMID: 23792087
- PMCID: PMC3795896
- DOI: 10.1016/j.pharmthera.2013.06.007
Multiplicity of effectors of the cardioprotective agent, diazoxide
Abstract
Diazoxide has been identified over the past 50years to have a number of physiological effects, including lowering the blood pressure and rectifying hypoglycemia. Today it is used clinically to treat these conditions. More recently, another important mode of action emerged: diazoxide has powerful protective properties against cardiac ischemia. The heart has intrinsic protective mechanisms against ischemia injury; one of which is ischemic preconditioning. Diazoxide mimics ischemic preconditioning. The purpose of this treatise is to review the literature in an attempt to identify the many effectors of diazoxide and discuss how they may contribute to diazoxide's cardioprotective properties. Particular emphasis is placed on the concentration ranges in which diazoxide affects its different targets and how this compares with the concentrations commonly used to study cardioprotection. It is concluded that diazoxide may have several potential effectors that may potentially contribute to cardioprotection, including KATP channels in the pancreas, smooth muscle, endothelium, neurons and the mitochondrial inner membrane. Diazoxide may also affect other ion channels and ATPases and may directly regulate mitochondrial energetics. It is possible that the success of diazoxide lies in this promiscuity and that the compound acts to rebalance multiple physiological processes during cardiac ischemia.
Keywords: 2,4-dinitrophenol; 5-hydroxydecanoate; 5HD; ATP-sensitive K(+) channel; Cardioprotection; DNP; Diazoxide; I/R injury; IPC; Ischemia; Ischemic preconditioning; K(ATP) channel; K(ATP) channels; Mitochondria; ROS; SDH; ischemia/reperfusion injury; ischemic preconditioning; mitochondrial membrane potential; reactive oxygen species; succinate dehydrogenase; ΔΨm.
Copyright © 2013 Elsevier Inc. All rights reserved.
Conflict of interest statement
The author declares that there are no conflicts of interest
Figures


References
-
- Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, Komaru T, Kanatsuka H, Shirato K. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. Journal of Cardiovascular Pharmacology. 1995;26:541–547. - PubMed
-
- Akao M, Ohler A, O’Rourke B, Marban E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circulation Research. 2001;88:1267–1275. - PubMed
-
- Al-Dadah AS, Voeller RK, Schuessler RB, Damiano RJ, Jr., Lawton JS. Maintenance of myocyte volume homeostasis during stress by diazoxide is cardioprotective. Annals of Thoracic Surgery. 2007;84:857–862. - PubMed
-
- Alcindor D, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology. 2004;100:547–554. - PubMed
-
- Antoine MH, Berkenboom G, Fang ZY, Fontaine J, Herchuelz A, Lebrun P. Mechanical and ionic response of rat aorta to diazoxide. European Journal of Pharmacology. 1992;216:299–306. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous